opc 12759 has been researched along with Esophageal Reflux in 5 studies
rebamipide: structure in first source; RN refers to (+-)-isomer; inhibits gastric xanthine oxidase
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aimed to detect safety signals of rebamipide and search for adverse events (AEs) of rebamipide that are more common than those of other drugs for peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD) in the elderly population." | 1.72 | Frequently reported adverse events of rebamipide compared to other drugs for peptic ulcer and gastroesophageal reflux disease. ( Jang, E; Jeong, JE; Kim, MG; Lee, JY; Park, M, 2022) |
| "Using rebamipide in the treatment of gastroesophageal reflux disease is justified because this drug has a unique mechanism of action, which eliminating the main stages of pathogenesis of the disease." | 1.56 | [Rebamipide using in gastroesophageal reflux disease treatment]. ( Gonik, MI; Ivashkin, VT; Trukhmanov, AS, 2020) |
| "Pantoprazole (5 mg/kg) was administered intraperitoneally to the PPI and PPI+R groups." | 1.48 | Additive Effects of Rebamipide Plus Proton Pump Inhibitors on the Expression of Tight Junction Proteins in a Rat Model of Gastro-Esophageal Reflux Disease. ( Choi, YK; Chung, JW; Gweon, TG; Kim, BW; Kim, CW; Kim, HG; Kim, JS; Park, JH; Park, SM, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jang, E | 1 |
| Park, M | 1 |
| Jeong, JE | 1 |
| Lee, JY | 1 |
| Kim, MG | 1 |
| Ivashkin, VT | 1 |
| Trukhmanov, AS | 1 |
| Gonik, MI | 1 |
| Gweon, TG | 1 |
| Park, JH | 1 |
| Kim, BW | 1 |
| Choi, YK | 1 |
| Kim, JS | 1 |
| Park, SM | 1 |
| Kim, CW | 1 |
| Kim, HG | 1 |
| Chung, JW | 1 |
| Yoshida, N | 1 |
| Kamada, K | 1 |
| Tomatsuri, N | 1 |
| Suzuki, T | 1 |
| Takagi, T | 1 |
| Ichikawa, H | 1 |
| Yoshikawa, T | 1 |
| Adachi, K | 1 |
| Furuta, K | 1 |
| Miwa, H | 1 |
| Oshima, T | 1 |
| Miki, M | 1 |
| Komazawa, Y | 1 |
| Iwakiri, K | 1 |
| Furuta, T | 1 |
| Koike, T | 1 |
| Shimatani, T | 1 |
| Kinoshita, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-blinded, Placebo-controlled Pilot Study to Evaluate the Efficacy and Safety of Rebamipide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis (REPAIR)[NCT02755753] | Phase 4 | 143 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for opc 12759 and Esophageal Reflux
| Article | Year |
|---|---|
Management of recurrence of symptoms of gastroesophageal reflux disease: synergistic effect of rebamipide with 15 mg lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Alanine; Anti-Ulcer Agents; Drug Synergism; Drug Ther | 2010 |
A study on the efficacy of rebamipide for patients with proton pump inhibitor-refractory non-erosive reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Alanine; Dose-Response Rela | 2012 |
3 other studies available for opc 12759 and Esophageal Reflux
| Article | Year |
|---|---|
Frequently reported adverse events of rebamipide compared to other drugs for peptic ulcer and gastroesophageal reflux disease.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Alanine; Gastroesophageal Reflux; Humans; Peptic Ulce | 2022 |
[Rebamipide using in gastroesophageal reflux disease treatment].
Topics: Alanine; Anti-Ulcer Agents; Gastroesophageal Reflux; Humans; Proton Pump Inhibitors; Quinolones; Vas | 2020 |
Additive Effects of Rebamipide Plus Proton Pump Inhibitors on the Expression of Tight Junction Proteins in a Rat Model of Gastro-Esophageal Reflux Disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alanine; Animals; Anti-Ulcer Agents; Disease Models, Animal | 2018 |